Pharming Group NV Sponsored ADR PHAR 深 滬
等待開盤 04-01 09:30:00 美东时间
16.64
+0.630
+3.94%
華盛通- 最 高16.82
- 今 開16.50
- 成交量 1.81万股
- 最 低 16.36
- 昨 收 16.01
- 總市值 11.59亿
- 52周最高 21.34
- 市盈率 靜 414.96
- 換手率 0.03%
- 52周最低 8.00
- 委 比 -58.73%
- 總股本 6966.88万
- 歷史最高 21.99
- 量 比 0.67
- 振 幅 2.87%
- 歷史最低 6.10
- 每 手 1
- 風險率 3.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pharming granted EU backing for rare immunodeficiency therapy
Pharming Group (PHAR) announced on Friday that an expert panel of the European Medicines Agency, the EU drug regulator, issued a positive opinion recommending marketing authorization for Joenja, a tre...
03-28 00:10
美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
Pharming Group's Joenja Approved In Japan As First Targeted Treatment For Activated PI3K Delta Syndrome In Patients Aged 4 Years And Older
First approved treatment in Japan for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)Approval is based on positive Phase III data from multinational and Japanese studies in patients aged 12 years and
03-24 14:17
Pharming Group NV Publishes Transcript of 4Q/FY 2025 Results Call
Pharming Group NV Publishes Transcript of 4Q/FY 2025 Results Call Pharming held a Q4 and full-year 2025 results call attended by CEO Fabrice Chouraqui, Chief Commercial Officer Leverne Marsh, Chief Medical Officer Anurag Relan and CFO Kenneth Lynard, with analysts including Lucy Codrington, Joseph P
03-19 17:54
美股大行评级 | 韦德布什升美光科技目标价升至500美元，维持"跑赢大市"评级
今日重点评级关注：Piper Sandler：维持Allogene疗法"超配"评级，目标价从7美元升至8美元；B. Riley证券：维持Oncology Institute"买入"评级，目标价从6美元升至8美元
03-16 18:19
Oppenheimer Reiterates Outperform on Pharming, Lowers Price Target to $41
Oppenheimer analyst Jeff Jones reiterates Pharming (NASDAQ:PHAR) with a Outperform and lowers the price target from $42 to $41.
03-14 01:15
Earnings Scheduled For March 12, 2026
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is likel...
03-12 19:11
Pharming beats top-line estimates; introduces FY26 outlook
Pharming press release (PHAR): Q4 GAAP EPS of $0.01 in-line. Revenue of $106.5M (+14.9% Y/Y) beats by $0.6M. RUCONEST® revenues amounted to US$86.7 million, a 9% increase compared to the fourth quarte...
03-12 14:33
Pharming Affirms FY2026 Sales Guidance of $405.000M-$425.000M
For 2026, the Company anticipates:Total revenues between US$405 million and US$425 million (8% to 13% growth), with quarterly fluctuations expected.Total operating expenses between US$330 million and US$335 million
03-12 14:10
Pharming Q4 EPS $0.07 Beats $0.01 Estimate, Sales $106.500M Beat $105.190M Estimate
Pharming (NASDAQ:PHAR) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.01 by 775 percent. This is a 40 percent increase over earnings of $0.05 per share from the same period
03-12 14:06
